Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin/PLD vs Platinum Continuation in Recurrent Ovarian Cancer
NCT03690739Phase 3Terminated
- Sponsor
- AGO Research
- Start
- Aug 2019
- Primary completion
- Mar 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trabectedin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AGO Research. Started Aug 2019; status: terminated.
02
Drugs
trabectedin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03690739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690739.